Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Sci Signal ; 13(618)2020 02 11.
Article in English | MEDLINE | ID: mdl-32047117

ABSTRACT

The serotonin (5-hydroxytrypatmine) receptor 5-HT6 (5-HT6R) has emerged as a promising target to alleviate the cognitive symptoms of neurodevelopmental diseases. We previously demonstrated that 5-HT6R finely controls key neurodevelopmental steps, including neuronal migration and the initiation of neurite growth, through its interaction with cyclin-dependent kinase 5 (Cdk5). Here, we showed that 5-HT6R recruited G protein-regulated inducer of neurite outgrowth 1 (GPRIN1) through a Gs-dependent mechanism. Interactions between the receptor and either Cdk5 or GPRIN1 occurred sequentially during neuronal differentiation. The 5-HT6R-GPRIN1 interaction enhanced agonist-independent, receptor-stimulated cAMP production without altering the agonist-dependent response in NG108-15 neuroblastoma cells. This interaction also promoted neurite extension and branching in NG108-15 cells and primary mouse striatal neurons through a cAMP-dependent protein kinase A (PKA)-dependent mechanism. This study highlights the complex allosteric modulation of GPCRs by protein partners and demonstrates how dynamic interactions between GPCRs and their protein partners can control the different steps of highly coordinated cellular processes, such as dendritic tree morphogenesis.


Subject(s)
Cyclic AMP/metabolism , Dendrites/metabolism , Receptors, Serotonin/metabolism , Signal Transduction , Animals , Cell Line, Tumor , Cell Movement , Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclin-Dependent Kinase 5/genetics , Cyclin-Dependent Kinase 5/metabolism , Mice , Morphogenesis , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neurites/metabolism , Neurons/cytology , Neurons/metabolism , Protein Binding , Receptors, N-Methyl-D-Aspartate/genetics , Receptors, N-Methyl-D-Aspartate/metabolism , Receptors, Serotonin/genetics
2.
Transl Psychiatry ; 8(1): 197, 2018 09 21.
Article in English | MEDLINE | ID: mdl-30242222

ABSTRACT

The mu opioid receptor (MOR) plays a critical role in modulating social behavior in humans and animals. Accordingly, MOR null mice display severe alterations in their social repertoire as well as multiple other behavioral deficits, recapitulating core and secondary symptoms of autism spectrum disorder (ASD). Such behavioral profile suggests that MOR dysfunction, and beyond this, altered reward processes may contribute to ASD etiopathology. Interestingly, the only treatments that proved efficacy in relieving core symptoms of ASD, early behavioral intervention programs, rely principally on positive reinforcement to ameliorate behavior. The neurobiological underpinnings of their beneficial effects, however, remain poorly understood. Here we back-translated applied behavior analysis (ABA)-based behavioral interventions to mice lacking the MOR (Oprm1-/-), as a model of autism with blunted reward processing. By associating a positive reinforcement, palatable food reward, to daily encounter with a wild-type congener, we were able to rescue durably social interaction and preference in Oprm1-/- mice. Along with behavioral improvements, the expression of marker genes of neuronal activity and plasticity as well as genes of the oxytocin/vasopressin system were remarkably normalized in the reward/social circuitry. Our study provides further evidence for a critical involvement of reward processes in driving social behavior and opens new perspectives regarding therapeutic intervention in ASD.


Subject(s)
Autism Spectrum Disorder/therapy , Behavior Therapy , Behavior, Animal , Receptors, Opioid, mu/genetics , Reward , Social Behavior , Animals , Applied Behavior Analysis , Autism Spectrum Disorder/genetics , Disease Models, Animal , Female , Male , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Neuronal Plasticity/genetics
3.
Bull Cancer ; 105(10): 955-966, 2018 Oct.
Article in French | MEDLINE | ID: mdl-30100047

ABSTRACT

Small cell lung cancer accounts for 14% of all lung cancers. It remains a major challenge for oncology as the progresses made in the past three decades are modest. After a rapid overview of current knowledge regarding somatic genomic alterations, this state-of-art addresses pathways to improve small-cell lung cancer outcome such as the targeting of DNA damage repair mechanisms firstly anti-PARPs, inhibitory molecules of EZH2, derepression of the NOTCH pathway, rovalbituzumab-tesirine, inhibition of serine/threonine Aurora A kinase, temozolomide and its dependence on methylation of the MGMT promoter. This first chapter suggests the beginning of precision medicine in small cell lung cancer. The last section focuses on the development of immuno-oncological agents and the information collected from phase 1 and 2 studies: the low intensity of PD-L1 tissue expression and the possible relationship of the activity of these agents as a function of tumor mutational burden are pointed out.


Subject(s)
Antineoplastic Agents/therapeutic use , Lung Neoplasms/drug therapy , Small Cell Lung Carcinoma/drug therapy , Antibodies, Monoclonal, Humanized/therapeutic use , Aurora Kinase A/antagonists & inhibitors , Benzodiazepinones/therapeutic use , DNA Damage , DNA Modification Methylases/metabolism , DNA Repair , DNA Repair Enzymes/metabolism , Dacarbazine/analogs & derivatives , Dacarbazine/therapeutic use , Enhancer of Zeste Homolog 2 Protein/antagonists & inhibitors , Humans , Immunoconjugates/therapeutic use , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use , Protein Serine-Threonine Kinases/antagonists & inhibitors , Receptors, Notch/metabolism , Small Cell Lung Carcinoma/genetics , Small Cell Lung Carcinoma/pathology , Temozolomide , Tumor Suppressor Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...